

Submission

[Home > Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/07/2016
Deadline Date	29/07/2016
Date Submitted	28/07/2016
Type	Performance in Delivery
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 12 of 12.
Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Commen
12216	15/WM/0457	195511	DARATUMUMAB: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Pr	Number Agreed	6	6	Not Available / Not Agreed		5		0	Recruitment Finished	
12217	15/LO/1807	187302	Checkmate 331 An Open-label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with resectable small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331	Number Agreed	7	7	Not Available / Not Agreed		1		0	Recruitment Finished	
12218	13/EM/0348	122371	Monoprost compared with Lumigan in POA glaucoma/ocular hypertension	Number Agreed	6	6	Date Agreed	30/04/2016	0		0	Recruitment Finished	
12220	14/WM/1055	152229	AB12006 - A prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-Fluorouracil and folinic acid) to placebo!	Number Agreed	6	6	Date Agreed	01/03/2016	1		0	Recruitment Finished	
12221	15/EM/0344	183906	MORAb-009-201 A randomised, double-blind, placebo-controlled study of the safety and efficacy of amaxukimab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma	Number Agreed	3	3	Not Available / Not Agreed		1		0	Recruitment Finished	
12223	15/LO/0940	179018	Victoria: GS-US-312-0118 A phase 3 randomised open-label study evaluating the efficacy and safety of idelalisib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab for previously untreated chronic lymphocytic l	Number Agreed	4	4	Not Available / Not Agreed		0		0	Recruitment Finished	
12225	15/LO/0691	174324	CHECKMATE 171: BMS-936558 A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen	Number Agreed	36	36	Date Agreed	15/05/2021	14		0	Recruitment Finished	
12244	15/EM/0400	178129	SOPHIA - A Phase 3, Randomised Study of Margatuximab Plus Chemotherapy vs Testuzumab Plus Chemotherapy in the Treatment of Patients with HER2-Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 therapies and Require Systemic Treatment	Number Agreed	5	5	Date Agreed	31/01/2017	0		0	Recruitment Finished	
12245	13/NW/0501	123836	QUAZAR CC-486-AML-001: A Phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid Leukemia	Number Agreed	4	4	Date Agreed	01/05/2016	0		0	Recruitment Finished	
12491	15/EE/0326	185205	Seattle Genetics: SGN35-023 A randomised, open label, phase 2 study of rituximab and bendamustine with or without brentuximab vedotin for relapsed or refractory CD30-positive diffuse large B-cell lymphoma	Number Agreed	10	10	Not Available / Not Agreed		0		0	Recruitment Finished	

12492	15/LO/1419	183975	PEARLS: A randomised, phase 3 trial with anti-PD-2 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	Number Agreed	20	20	Date Agreed	01/06/2016	0	01/06/2016	0	Recruitment Finished
12493	14/YH/1056	147421	AB1004 Study- A Multicenter, Randomised, Open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of mastihib with dexamethasone, gemcitabine with dexamethasone and the combination of mastihib, gemcitabine and dexametha	Number Agreed	4	4	Not Available / Not Agreed		0		0	Recruitment Finished

Showing records 1 to 12 of 12.
Pages: 1

< Back